PF-06648671
- Generic Name
- PF-06648671
An Open-Label, 2 Treatment Period,Study To Study The Drug Interaction Between Repeated Doses Of Itraconazole And Single Dose Pharmacokinetics (PK) Of PF-06648671 In Healthy Adults.
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT02883114
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Phase 1 Study To Characterize The Safety, Tolerability, PK And PK Of Repeat Doses Of PF-06648671 In Healthy Adults And Healthy Elderly Subjects
Phase 1
Completed
- Conditions
- Healthy Adult Subjects and Healthy Elderly Subjects
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2016-11-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 92
- Registration Number
- NCT02440100
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on β-Amyloid (Aβ) Concentrations in Cerebrospinal Fluid (CSF)
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT02407353
- Locations
- 🇺🇸
Glendale Adventist Medical Center, Glendale, California, United States
🇺🇸California Clinical Trials Medical Group, Inc., Glendale, California, United States
A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects
- First Posted Date
- 2014-12-15
- Last Posted Date
- 2015-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT02316756
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath